

DirectConnect

Inside Yale Cancer Center

April 14, 2023

Dear Colleagues,

Last week, the National Cancer Institute and Dr. Monica Bertagnolli released **THE NATIONAL CANCER PLAN**. The plan provides a roadmap in response to President Biden's 2022 commitment to "end cancer as we know it today," by reducing cancer mortality by at least 50% in the next 25 years and improving "the experience of people living with and surviving cancer, their families, and caregivers." The 25-page document contains the clear message that we can, and must, do better.

The plan's focus "is to achieve a society where every person with cancer lives a full and active life, and to prevent most cancers so that few people need to face this diagnosis." It calls upon clinicians, researchers, healthcare systems, public health officials, foundations, industry, and local, state, and federal governments to work together to achieve the mission.

Dr. Bertagnolli and colleagues acknowledge the recent leaps forward in cancer research and treatment and urges more of the same, but its emphasis is on two critical themes: the absolute need to address healthcare disparities and care delivery, from preventative to palliative; and the role of research as the robust driver of the change. Basic, translational, clinical, and population research are all essential, and teamwork is paramount.

A national plan that echoes our own goals here at YCC/Smilow is both affirming and energizing. The first three of eight of the plan goals—improved prevention, detection and effective treatment of cancer—are followed by five more broad goals: eliminate inequities, deliver optimal care, engage every person, maximize data utility, and optimize the workforce. Each is followed by strategies for achieving them, including critical research initiatives and implementation efforts. Finally, there is a call to action, and notably, unified action.

I have been fortunate to know Dr. Bertagnolli for the last 25 years as we worked together closely in our previous institutions. She has boundless energy, is incapable of speaking anything but the truth, and is always ready to eliminate red tape. She is ideally suited for her role as NCI director. No single individual can accomplish the goals outlined above, but as the leader of the NCI she is a powerful force.

We have a great deal of work ahead of us at Yale and beyond. With hard work, optimism, collaboration, and resources, I believe that YCC/Smilow can contribute to the broad and ambitious goals outlined in the National Cancer Plan.

Eric P. Winer, MD

Director, Yale Cancer Center

Physician-in-Chief, Smilow Cancer Network

Yale
NewHaven
Health
Smilow Cancer
Hospital

Yale **CANCER**
CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

News Center



New Data on Novel Treatment for Drug-Resistant Brain Cancers



[Read More](#)

[Updates in Targeted Therapies](#)

Announcements



Yale Advances to be Presented at AACR Annual Meeting

Yale Cancer Center and Smilow Cancer Hospital physicians and scientists are presenting research studies at the 2023 American Association for Cancer Research (AACR) Annual Meeting at the Orange County Convention Center in Orlando, Florida beginning today through Wednesday, April 19. Research teams will reveal the latest data on treatments and diagnostic advances as well as new findings on head and neck, lung, metastatic, and other cancers.

This year's program will feature hundreds of oral and poster presentations, educational sessions, and workshops in 24 specialty tracks, all highlighting the theme: "Advancing the Frontiers of Cancer Science and Medicine." Congratulations to all the Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians for their research being recognized at AACR! Some key presentations include: [Read More](#)


Notables

Patricia LoRusso, DO, PhD (h), has been elected to the **2023 Class of Fellows of the AACR Academy** by the **American Association for Cancer Research**. Dr. LoRusso, while also being recently elected to serve as AACR President-Elect, will become one of 23 Fellows, and was recognized "for unrivaled clinical cancer research contributions including expertly and extensively designing and executing innovative early-phase clinical trials; and for improving therapeutic outcomes to not only reduce mortality rates, but also enhance the quality of life for patients with cancer."

Jacquelyne Gaddy, MD, MSc, Assistant Professor of Medicine (Medical Oncology) and a member of Yale Cancer Center's Cancer Prevention and Control Research Program, has received a Spring **2023 ECOG-ACRIN**

Minority Scholarship Travel Award from the ECOG-ACRIN Cancer Research Group to attend the ECOG-ACRIN Semi-Annual Group May 3-5 in Chicago.

Updates in Targeted Therapies, Management Strategies for Non-Small Cell Lung Cancer



[Read More](#)

Looking for Silver Linings After Conquering Cancer, Wilton's Donna Savage Aims to Help Others



[Read More](#)

Think You're Too Young to Need a Colonoscopy? Think Again



[Read More](#)

New Findings Support Novel Combination Treatment for Head and Neck Cancers



Francesca Montanari, MD, Assistant Professor of Clinical Medicine (Hematology), has been selected to attend the **2023 Early Career Women Faculty Leadership Development Seminar** hosted by the Association of American Medical Colleges in Boston this July.

Craig Crews, PhD, John C. Malone Professor of Molecular, Cellular & Developmental Biology, Professor of Chemistry, Pharmacology, and Management, and a member of Yale Cancer Center's Developmental Therapeutics Research Program, was honored on April 4 with an **Ivy Award**, part of New Haven's annual Elm-Ivy Awards presentation. Ivy Awards honor recipients affiliated with Yale. Crews was cited as creator of the job-training program BioLaunch.

DEI Update

Women's Leadership Development Program

The Office of Women in Medicine and Science (OWiMS) and the Office of Diversity, Equity, and Inclusion at Yale School of Medicine offer the Women's Leadership Development Program (WLPD).

The WLPD unfolds across five, two-hour sessions that provide a mix of didactic and experiential instruction in a virtual group format. Course content is designed to help faculty acquire foundational communication and organizational skills, establish career goals, learn the ins and outs of peer coaching, and articulate leadership vision and purpose. The program culminates in each participant's creation of an individualized professional development plan articulating actionable career goals for the near term. Over the course of the program, participants are also given ample opportunity to build enduring, supportive relationships with one another and to identify how to further grow their professional networks. To date, recruitment has focused on early career faculty, with the belief that gaining fundamental leadership skills at the beginning of one's career can yield fruit for years to come.


WLPD was developed and is delivered by Daryn David, PhD, faculty member at the Child Study Center and associate director for leadership development in the Office of Diversity, Equity, & Inclusion and the Office of Academic & Professional Development at Yale School of Medicine. Early career women who would like more information about the program can contact **Dr. David**.

Rapid Case Ascertainment Shared Resource

The Rapid Case Ascertainment Shared Resource has been a shared resource at Yale Cancer Center since 1995. Working as an agent of the Connecticut Tumor Registry, RCA facilitates population-based studies of cancer for YCC investigators, as well as outside investigators. As the needs of YCC investigators have evolved to require more research staff support for non-therapeutic trials, RCA has broadened and expanded its scope to provide support to YCC investigators in their non-therapeutic studies as well.

This includes YCC investigators that conduct projects through the Veteran's Health Administration (VHA).

"We assist cancer researchers in implementing and executing their studies by providing high-quality and cost-effective study management, cancer case



[Read More](#)

Researchers Explore the Role of Cellular Plasticity in Cancer




[Read More](#)

Cancer Patients Choose Lifestyle Over More Aggressive Treatments



[Read More](#)

First Single Molecule Microscopic Visualization of the Full-length Human BRCA2 Protein Binding to DNA Revealed



identification, patient enrollment and interview, medical record abstraction, and specimen collection services so that investigators can accomplish their scientific goals,” said Rajni Mehta, MPH, Director of RCA.

The RCA coordinates directly with Yale Pathology Tissue Services, or other hospital pathology labs, to obtain pathology specimens or histology services. They also manage blood and other specimen collections (i.e., stool, cerebral spinal fluid, biopsy cores) at the Smilow Cancer Hospital Care Centers and assist with obtaining IRB approvals. By helping with these processes, RCA provides a service that would be difficult for individual PIs to achieve on their own in a limited study time period.

The RCA is rapidly expanding to support YCC Investigators’ need for non-therapeutic study management and support. This includes not only specimen collections, transportation, and shipment from the Smilow Cancer Hospital Care Centers, but assistance to YCC investigators with chart review and patient contact studies that need administrative and research help.

For more information, please contact: **Rajni Mehta**.

Exploring the Microbiome


Please join the Yale community for a day-long **event** showcasing collaborative ground-breaking microbiome research across Yale West Campus! The event will feature a keynote talk by Charis Eng, MD, PhD, Chair of the Genomic Medicine Institute, and Director of the Center for Personalized Genetic Healthcare at the Cleveland Clinic. We will also hear exceptional talks from scientists at the West Campus on work relating to the microbiome, enjoy a networking lunch and a poster social.

The event will be held in-person on **Tuesday, May 9, 2023**, Yale West Campus Conference Center, 800 West Campus Drive, West Haven, CT. Breakfast is from 8:30am and the program runs from 9:00am to 5:30pm. Please **register to attend**.

Employee Profile: Meina Wang, PhD

Director for Education and Translational Research in the Section of Medical Oncology, Meina Wang, PhD, has always been fascinated by science and how things work. This carried through to

graduate school, and her pursuit of a PhD in Pathology. She then completed a postdoctoral fellowship in Internal



[Read More](#)



Recently on Yale Cancer Answers, medical oncologist Dr. Michael Grant discussed targeted and immunotherapy approaches to the treatment of non-small cell lung cancer. Listen on Connecticut Public Radio or download our podcast from iTunes.



[Read More](#)

Meet Michael Hurwitz, MD, PhD, a medical oncologist at Smilow Cancer Hospital. Dr. Hurwitz cares for patients with genitourinary malignancies, including prostate cancer, as well as patients with melanoma.

A recent patient of Dr. Hurwitz shared the following, “Dr. Hurwitz is very thorough, professional, and does a great job of explaining my treatments and options.”





Medicine/Endocrinology at Yale, and has since received several research awards as well as published numerous papers (most recently in *Nature Medicine* in 2021 and in *Cancer Cell* in 2022). Her main area of focus has been lung cancer.

As part of her role in Translational Research, working closely with Dr. Roy S. Herbst, Deputy Director of Yale Cancer Center and Assistant Dean for Translational Research, Dr. Wang is responsible for overseeing and managing large multi-site and global oncology studies such as the AstraZeneca-Yale Oncology Alliance, a 12-project alliance with more than \$15M in funds aimed at speeding translational and clinical research and developing lifesaving, next-generation cancer therapies. Dr. Wang is also responsible for identifying and initiating new collaborations, between investigators at Yale and companies, for new drug developments and disease treatment, such as the Lung Injury Studio, a new initiative in collaboration with the Yale School of Medicine Office of Team Science.

In her support of Education, Dr. Wang manages the Cancer Research Training and Education Coordination (CRTEC) component of the CCSG and works closely with Dr. Harriet Kluger, Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology and Director of the Yale SPORE in Skin Cancer, to develop programs that contribute to the training and education of mentees across a broad spectrum of educational stages from high school students to junior faculty. She also oversees and manages both the Heme/Onc T32 training grant for fellows, which is currently in the renewal stage, and the Yale Cancer Center K12 Calabresi Immuno-Oncology Training Program (IOTP) for junior faculty.

“Cancer constitutes a significant societal burden, and I aspire to apply the expertise and knowledge I have gained to contribute to the advancement of treatment options for patients. The ultimate goal is to achieve a cure for all types of cancer and deliver optimal care for patients,” said Dr. Wang.

Dr. Herbst commented, “Meina’s knowledge of and dedication to furthering collaborations in translational research at Yale Cancer Center and beyond is unmatched and has helped to bring several promising new therapeutics from the laboratory to patients.”

“The education apparatus of the Cancer Center has benefitted immensely from Dr. Wang’s wisdom as well as from her unwavering dedication to training the next generation of cancer researchers,” said Dr. Kluger.

Recent Publications

Dhiman, A., Kothary, V., Witmer, H. D. D., Bregio, C., Sood, D., Ong, C. T., Polite, B., Eng, O. S., Shergill, A., & Turaga, K. K.

Role of Tumor-informed Personalized ctDNA Assay in Informing Recurrence in Patients with Peritoneal Metastases from Colorectal and High-grade Appendix Cancer Undergoing Curative Intent Surgery.



Read More

“Nationally what we have been observing are increasing trends of early onset cancers. It is a really important area to address for a number of reasons. One is that oftentimes, cancer in younger adults tend to be more aggressive. There can be some differences in the responses to therapies, and these patients can have unique psychosocial needs – supportive needs that have to be brought into their care in order for them to really launch into survivorship,” Dr. Veda Giri, Chief, Division of Clinical Cancer Genetics and Director, Early-Onset Cancer Program.



Watch Now

Using genetic sequencing, researchers identify the total number of mutations in a tumor and determine the tumor mutational burden, or TMB. To estimate a patient’s TMB, tumor-only platforms try to filter out germline mutations by comparing the genetic data from the patient’s tumor with genetic information drawn from large public databases, but new research reveals that 80 to 85 percent of the samples in those databases are from white patients.



High-grade appendiceal cancer undergoing minimally-invasive surgery.

Annals of surgery, 10.1097/SLA.0000000000005856.

[Read More](#)

Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, Kato T, Goldman JW, Laktionov K, Kim SW, Yu CJ, Vu HV, Lu S, Lee KY, Mukhametshina G, Akewanlop C, de Marinis F, Bonanno L, Domine M, Shepherd FA, Urban D, Huang X, Bolanos A, Stachowiak M, Tsuboi M.

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-III A Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.

Journal of Clinical Oncology. 2023 Apr 1.

[Read More](#)

Berger, Y., Gadiraju, M., Dhiman, A., Gilliam, K., Opalecky, B., Chen, H., Helgeson, M., Eng, O. S., Husain, A. N., Drazer, M. W., Kindler, H. L., Churpek, J. E., & Turaga, K. K.

Surgical phenotype of patients with peritoneal mesothelioma and a germline mutation.

Cancer, 10.1002/cncr.34763.

[Read More](#)

Zhang D, Deng Y, Kukanja P, Agirre E, Bartosovic M, Dong M, Ma C, Ma S, Su G, Bao S, Liu Y, Xiao Y, Rosoklija GB, Dwork AJ, Mann JJ, Leong KW, Boldrini M, Wang L, Haeussler M, Raphael BJ, Kluger Y, Castelo-Branco G, Fan R.

Spatial epigenome-transcriptome co-profiling of mammalian tissues.

Nature. 2023 Apr.

[Read More](#)

Nyrop KA, Gaddy J, Charlot M.

Obesity, Cancer, and Health Equity.

American Journal of Preventative Medicine. 2023 Apr.

[Read More](#)

Berman R, Laird BJA, Minton O, Monnery D, Ahamed A, Boland E, Droney J, Vidrine J, Leach C, Scotté F, Lustberg MB, Lacey J, Chan R, Duffy T, Noble S.

The Rise of Supportive Oncology: A Revolution in Cancer Care.

Clinical Oncology (R Coll Radiol). 2023 Apr.

[Read More](#)

Yao J, Novosel M, Bellampalli S, Kapo J, Joseph J, Prsic E.

Lung Cancer Supportive Care and Symptom Management.

Hematology/Oncology Clinics North America. 2023 Apr 4.

[Read More](#)

Anczuków O, Airhart S, Chuang JH, Coussens LM, Kuchel GA, Korstanje R, Li S, Lucido AL, McAllister SS, Politi K, Polyak K, Ratliff T, Ren G, Trowbridge JJ, Ucar D, Palucka K.

Challenges and opportunities for modeling aging and cancer.

Cancer Cell. 2023 Apr 10.

[Read More](#)

Grant MJ, Woodard GA, Goldberg SB.

The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer.

Hematology/Oncology Clinics North America. 2023 Apr 4.

[Read More](#)

Goldberg SB, Herbst RS.

Advances and Opportunities in the Management of Lung Cancer.

Hematology/Oncology Clinics North America. 2023 Apr 4.

[Read More](#)

Unger JM, Qian L, Redman MW, Tavernier SS, Minasian L, Sigal EV, Panadimitrakopoulou VA, Leblanc M, Cleeland CS, Dzingirga SA, Summers T J

[Read More](#)

Rukiye Maras has been a familiar face for our patients and staff for 15 years. She joined Yale New Haven Health as a medical assistant in 2008 and is one of our dedicated Ambulatory Care Associates (ACAs) at Smilow Cancer Hospital. Rukiye takes care of our patients with a welcoming, kind demeanor in the Phase I Clinic in 55 Park Street and on weekends can be found on the hematology unit on NP7. She takes great care to align with the YNHH standards of conduct and uses her inner conscience to guide her daily work to be the best for our patients with utmost efficiency.

Recently, Rukiye spearheaded a winter clothing drive in response to the massive earthquake that struck Turkey and Syria in early February. The kindness and generosity of our Smilow/YNHH family helped her to supersede her goals. "The YNHH family is a strong, cohesive group who thinks as one. When one group is hurt, even oceans away from us, the entire YNHH family is hurt and responds," Rukiye shared. She continued by thanking her manager, Camille Servodidio, and Sandy Marshall-Wray and Karen Underwood, RN for their support of her efforts, along with her family who helped to sort and deliver the donations to NYC for transport to Turkey and Syria.

Smilow Star



Thank you,
Rukiye Maras,
Ambulatory Care Associate
at Smilow Cancer Hospital!

Papadimitrakopoulou VA, Lebranc M, Cleeland CS, Dzingile SA, Summers TS, Chao H, Madhusudhana S, Villaruz L, Crawford J, Gray JE, Kelly KL, Gandara DR, Bazhenova L, Herbst RS, Gettinger SN, Moinpour CM. **Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.** *Journal of the National Cancer Institute.* 2023 Apr 11.

[Read More](#)

Ravi A, Hellmann MD, Arniella MB, Holton M, Freeman SS, Naranbhai V, Stewart C, Leshchiner I, Kim J, Akiyama Y, Griffin AT, Vokes NI, Sakhi M, Kamesan V, Rizvi H, Ricciuti B, Forde PM, Anagnostou V, Riess JW, Gibbons DL, Pennell NA, Velcheti V, Digumarthy SR, Mino-Kenudson M, Califano A, Heymach JV, Herbst RS, Brahmer JR, Schalper KA, Velculescu VE, Henick BS, Rizvi N, Jänne PA, Awad MM, Chow A, Greenbaum BD, Luksza M, Shaw AT, Wolchok J, Hacohen N, Getz G, Gainor JF. **Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.** *Nature Genetics.* 2023 Apr 6.

[Read More](#)

Dizman N, Austin M, Considine B, Jessel S, Schoenfeld D, Merl MY, Hurwitz M, Sznol M, Kluger H. **Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.** *Clinical Genitourinary Cancer.* 2023 Apr.

[Read More](#)

Tran TT, Caulfield J, Zhang L, Schoenfeld D, Djureinovic D, Chiang VL, Oria V, Weiss SA, Olino K, Jilaveanu LB, Kluger HM. **Lenvatinib or anti-VEGF in combination with anti-PD-1 differentially augments antitumor activity in melanoma.** *JCI Insight.* 2023 Apr 10

[Read More](#)

Bewersdorf JP, Huntington SF, Zeidan AM. **Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?** *Journal of National Comprehensive Cancer Network.* 2023 Apr 10.

[Read More](#)

Ajani JA, D'Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Farjah F, Gerdes H, Gibson M, Grierson P, Hofstetter WL, Ilson DH, Jalal S, Keswani RN, Kim S, Kleinberg LR, Klempner S, Lacy J, Licciardi F, Ly QP, Matkowskyj KA, McNamara M, Miller A, Mukherjee S, Mulcahy MF, Outlaw D, Perry KA, Pimiento J, Poultides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian NR, Pluchino LA. **Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.** *Journal of National Comprehensive Cancer Network.* 2023 Apr.

[Read More](#)

Sneider AP, Dhiman A, Morgan R, Tun S, Turaga KK, Eng OS. **Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy postoperative symptomatology: palliative care impact.** *BMJ Supportive & Palliative Care.* 2023 Apr 6.

[Read More](#)

Zeidan AM, Pollyea DA, Borate U, Vasconcelos A, Potluri R, Rotter D, Kiendrebeogo Z, Gaugler L, Prebet T, Strocchia M, Bonifacio G, Chen C. **Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.** *Annals of Hematology.* 2023 Apr.

[Read More](#)

[Read More](#)

Dr. Preston Sprenkle discussed innovative, less invasive techniques to treat prostate cancer on Yale Cancer Answers. New surgical options, including ablation and focal therapies, can improve accuracy and speed recovery. Listen on Connecticut Public Radio or download our podcast from iTunes.



[Read More](#)

#earlydetectionsaveslives #getscreened#colorectalcanerawarenessmonth

MYTH
I feel fine, so I don't need to worry about colon cancer screenings.

FACT
Many people diagnosed with colon cancer never felt any symptoms. Screening should begin at age 45.

[Read More](#)

 Congratulations to Akiko Iwasaki, PhD, @VirusesImmunity, on her inclusion on the STATUS List 2023 compiled by the medical and science news publication @statnews.

 We are pleased to share that Dr. Patricia LoRusso has been named a Fellow of the @AACR Academy, Class of 2023. The new class will be inducted into the Academy this weekend at #AACR23.

Bendell J, LoRusso P, Overman M, Noonan AM, Kim DW, Strickler JH, Kim SW, Clarke S, George TJ, Grimison PS, Barve M, Amin M, Desai J, Wise-Draper T, Eck S, Jiang Y, Khan AA, Wu Y, Martin P, Cooper ZA, Elgeiوشي N, Mueller N, Kumar R, Patel SP.

First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.

Cancer Immunology, Immunotherapy. 2023 Apr 5.

Read More

Funding and Award Opportunities

Diversity Enhancement Program in Oncology at Yale Cancer Center

The Diversity Enhancement Program in Oncology is an initiative established by the Section of Medical Oncology at YCC. The Program is designed to foster underrepresented in medicine (URiM) trainees' interest in careers in hematology/medical oncology (heme/onc) and to build a pipeline to bring URiM candidates to the YCC Heme/Onc Fellowship Program and YCC-Advanced T32 Training Program for Physician-Scientists.

The Diversity Enhancement Program in Oncology supports 2 URiM medical students or residents to spend an 8-week oncology rotation at Yale in summer 2023. The rotation will include an oncology clinical experience in conjunction with a clinical or translational research project. The selected medical student(s) or resident(s) will be mentored by YCC faculty and co-mentored by Heme/Onc T32 Fellows. The Section of Medical Oncology at YCC will cover the expenses including living, transportation, and research for up to \$5,000 per person.

Application Deadline: April 19, 2023

Read More

Yale SPORE in Lung Cancer Career Enhancement Program (CEP)

The CEP of the Yale SPORE in Lung Cancer has been established to educate the next generation of investigators committed to translational research in lung cancer. The CEP will provide support of up to \$50,000 to promising junior investigators and/or establish investigators who have not previously conducted lung cancer focused research.

Letters of Intent Due: April 21, 2023

Read More

Yale SPORE in Lung Cancer Developmental Research Program (DRP) Award

The DRP of the Yale SPORE in Lung Cancer provides seed money to investigators to support studies with a strong translational component that have the potential to evolve into, or be incorporated as, a full Yale SPORE in Lung Cancer project. The purpose is also to generate preliminary data or evidence of collaboration for new NCI grant applications.

Letters of Due: April 21, 2023

Read More

Translational Cancer Research for Basic Scientists Workshop

An intensive week-long introduction to translational cancer research – including cancer medicine, the clinical cancer research environment, and collaborative team science – for basic scientists who are predoctoral students and postdoctoral fellows, early-career scientists, and senior scientists in transition to translational research.

Application Deadline: May 2, 2023

Read More

Biomedical Knowledgebase (U24)

This FOA is designed to support biomedical knowledge bases. Biomedical knowledge bases under this announcement should have the primary function to extract, accumulate, organize, annotate, and link existing bodies of



Red dye 3 is also known as erythrosine, a synthetic dye derived from petroleum, explains Dr. Nicole Deziel @DezielLab_yale. It “is a food colorant that has been associated with #cancer in some animal studies.”



A dosing schedule for #MDM2 inhibitor #Milademetan was determined through this study. Milademetan had notable efficacy in patients w/advanced #liposarcomas, providing the foundation for a randomized phase III study.



.@DrRoyHerbstYale applauds launch of the Pragmatica-Lung study: “This treatment is a perfect option for the new pragmatic #clinicaltrial design to make sure clinical trials are available to all patients in their communities.”



We were pleased to host Dr. Ajai Chari for our annual Bove Lecture @SmilowCancer @Yale_LabMed. Watch Dr. Chari's presentation on advances in #MultipleMyeloma: <https://youtu.be/9yI2YSaJajM>



D. S. Fahmeed Hyder, PhD, Professor of @YaleRadiology & @YaleBme and a member of Yale Cancer Center's Radiobiology and Genome Integrity Research Program, has been named Head of #TrumbullCollege at @Yale.



We are looking forward to sharing the latest advances from @YaleCancer @SmilowCancer at #AACR23 starting on Friday, April 14! full list of presentations <https://bit.ly/3o0grB3> more information <http://bit.ly/3MzENvK>

@AACR



Dhanpat Jain, MD, Professor of Pathology and of Medicine (Digestive Diseases), was recognized by the @theNCI for lending his subject matter expertise to the #Cancer #PathologyCoding Histology & Registration Terminology (#CancerPathCHART).



Congratulations to Bohdan Pomahac, MD, @pomahacMD, Chief of Plastic and Reconstructive Surgery

to extract, accumulate, organize, annotate, and link growing bodies of information related to core datasets.

Application Deadline: May 8, 2023

Read More

Biomedical Data Repository (U24)

This FOA is designed to support biomedical data repositories. Biomedical data repositories under this announcement should have the primary function to ingest, archive, preserve, manage, distribute, and make accessible the data related to a particular system or systems.

Application Deadline: May 8, 2023

Read More

NCCN Pfizer Investigator-Sponsored Research Project to Evaluate the Effectiveness of Elranatamab in the Treatment of Multiple Myeloma

NCCN® is pleased to announce a collaboration with Pfizer Global Medical Grants to offer a new grant opportunity. They are seeking LOI for investigator-initiated research to support clinical research studies to further evaluate the effectiveness of elranatamab in the treatment of Multiple Myeloma.

Letters of Intent Due: May 10, 2023

Read More

R Accelerated Grant: this grant provides funding to scientists who are within their first 10 years of faculty appointment and focused on research in pediatric oncology that support ALSF's mission to find cures and better treatments for childhood cancers.

Application Deadline: May 11, 2023

'A' Award Grant: the 'A' Award is designed for the early career scientist who wants to establish a career in pediatric oncology research and does not have independent NIH funding.

Application Deadline: May 12, 2023

Read More

Robert A. Winn Diversity in Clinical Trials Award Program

The goal of the Robert A. Winn Career Development Award (Winn CDA) is to increase the diversity of patients enrolled in clinical trials, and ultimately to enhance the development of therapeutics for all populations.

Application Deadline: May 12, 2023

Read More

Yale Center for Gastrointestinal Cancers: 2023-2024 Seed Grant Program

This intramural seed grant program of the Center for Gastrointestinal Cancers (CGIC) is designed to spur team-based basic, translational, clinical, or population health research in GI cancers by providing pilot funding to support new or existing projects in early stages. Funds are intended to be used to formalize collaborations and acquire preliminary data that allow for

competitive submissions for extramural funding, including multi-PI R01 and program project grants. Two (2) projects will be funded for academic year 2023-2024.

Internal Submission Deadline: May 15, 2023

Read More

Impacts of climate change across the cancer control continuum (RO1/R21)

This NOFO aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. This includes, but is not limited to, studies to improve knowledge of the impact of climate change related environmental effects on cancer risks, control and behaviors.

Applications Open: RO1 on May 5, 2023 and R21 on May 16, 2023

Read More

and a pioneer in the field of plastic and reconstructive #surgery, recently appointed the Frank F. Kanthak Professor of Surgery (Plastics).



Dr. Ajai Chari will present

#GrandRounds today at 12pm:

"Multiple Myeloma: So Many Drugs, Yet So Few Cures." Please join in person or online via Zoom <http://bit.ly/43k9Npz>

#MultipleMyeloma



Dr. Veda Giri @vedangiri, Director, Early Onset Cancer Program at

@SmilowCancer, explains why it's important to have individualized care for patients between 18-49 years old.



Dr. Kiran Turaga @kturaga will present #GrandRounds today at

12pm on "Peritoneal Surface Malignancies: Novel therapeutics and insights."

Join in person or online via Zoom:

<http://bit.ly/3nCC6PO>



Research from Dr. Kiran Turaga @kturaga & team shows #ctDNA

levels predicted recurrence of #colorectalcancer w/peritoneal mets I & high-grade appendix cancer (HGA) in pts undergoing curative resection

Calendar

Advance Care Planning Education

Sessions: Discuss, Document, and Share

April 14, 9:00 AM

Learn More

Endocrinology Clinical Dilemma

April 14, 12:00 PM

Boyer Center for Molecular Medicine

Rucha Patki, MD

Learn More

Yale Cancer Answers

April 16, 7:30 PM

XR in adolescent and young adult oncology supportive care

Asher Marks, MD

Learn More

Regulation of Mcm2-7 Pools during

Eukaryotic DNA Replication

NCCN, Pfizer and Myovant RFP: Combination Therapy with Relugolix in the Treatment of Advanced Prostate Cancer

NCCN[®] is pleased to announce a collaboration with Pfizer Global Medical Grants and Myovant Sciences to offer a new grant opportunity. They are seeking proposals for investigator-initiated research to support clinical research studies to further evaluate the effectiveness of relugolix in combination with other therapies for the treatment of advanced prostate cancer.

Application Deadline: May 22, 2023

Read More

Yale Head and Neck SPORE (YHN-SPORE) Career Enhancement Program (CEP)

The CEP of the Yale Head and Neck SPORE has been established to educate the next generation of investigators committed to translational research in head and neck cancer. The CEP will provide support to promising junior investigators and/or establish investigators who have not previously conducted head and neck cancer focused research.

Full applications Due: Friday, May 26, 2023

Submit here

Yale Head and Neck SPORE (YHN-SPORE) Developmental Research Program (DRP)

The Yale Head and Neck SPORE's DRP provides seed money to investigators to support studies with a strong translational component that have the potential to evolve into, or be incorporated as, a full YHN-SPORE project or to generate preliminary data or evidence of collaboration for other new NIH grant applications.

Full applications Due: Friday, May 26, 2023

Submit here

DoD Ovarian Cancer Research Program

The Ovarian Cancer Research Program (OCRP) is currently accepting applications for five award mechanisms.

- **Clinical Trial Award:** supports rapid implementation of clinical trials with the potential to have a significant impact on ovarian cancer. **Pre-proposal due:** May 26, 2023
- **Clinical Translational Research Award:** supports correlative studies that address translational research in high-impact or unmet needs in ovarian cancer and have a clinical emphasis. **Pre-proposal due:** May 26, 2023

Read More

Liver Cancer Collaborative Projects with the Liver Cirrhosis Network (U01)

Through this NOFO, the NCI intends to establish collaborations between liver cancer investigators and the National Institute of Diabetes and Digestive and

Kidney Diseases (NIDDK)-funded Liver Cirrhosis Network (LCN) members to advance our understanding of hepatocellular carcinoma (HCC) as the result of liver cirrhosis and its etiologic risks, development, progression, early diagnosis, and treatment.

Application Deadline: June 2, 2023

Read More

Revision Applications to Support Research on Prevention and Cessation of Menthol Cigarette Use in Populations that Experience Health Disparities (R01)

As part of the ADVANCE: Advancing Prevention Research for Health Equity program, the NIH Office of Disease Prevention (ODP) within the Office of the Director Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) is soliciting revision applications (formerly called "competitive revisions") to active R01 grants to support studies that develop and evaluate menthol cigarette smoking cessation and prevention interventions for populations that experience health disparities.

Application Deadline: June 19, 2023

Read More

Eukaryotic DNA Replication

April 17, 11:00 AM

Sterling Hall of Medicine, I-Wing

Susan F Silva, BSc (Hon)

Learn More

Geriatric Grand Rounds

April 18, 4:00 PM

Patterns of Surveillance in Women with Elderly Breast Cancer

Elizabeth Berger, MD, MS, FACS

Learn More

Human and Translational Immunology Seminar Series

April 18, 4:00 PM

Brady Memorial Laboratory

Evolution of T cell fitness in the tumor microenvironment

Jaehyuk Choi, MD, PhD

Learn More

YCC Seminar

April 18, 5:00 PM

Winchester Building, WWW208

Harnessing the Immune System to Treat Lymphoma

Catherine S. Diefenbach, MD

Learn More

Yale PCCSM Grand Rounds

April 19, 3:00 PM

Lung Cancer Part 1: Advances in the Treatment Non-Small Cell Lung Cancer

Sarah Goldberg, MD, MPH

Learn More

Therapeutic Radiology Grand Rounds

April 20, 9:00 AM

Smilow Cancer Hospital at Yale New

Haven, LL505, Lower Level, North Pavilion

Hypofractionated RT for NSCLC

Alexander Sasse

Learn More

Cancer Genetics and Prevention Program Seminar

April 20, 2:30 PM

Claire Healy, MS, CGC

Learn More

Microbiology Graduate Seminar Series

April 20, 3:00 PM

Hope Memorial Building, 216

Peijun Zhang, MD

Learn More

Addressing the Primary Care Needs of Cancer Survivors (U01)

The purpose of this FOA is to support the development and testing of primary care practice (PCP)- and health system-level interventions and strategies to promote high quality care for adult cancer survivors during and/or after cancer treatment. The overall goal of this opportunity is to support high quality care for cancer survivors that integrates primary care from the point of diagnosis forward.

Application Deadline: July 24, 2023

[Read More](#)

DoD Prostate Cancer Research Program Funding Opportunities for FY23

- **Early Investigator Research Award (EIRA)** - supports research opportunities focused on prostate cancer for individuals in the early stages of their careers. **LOI Due:** August 3, 2023
- **Exploration – Hypothesis Development Award (EHDA)** - supports the exploration of highly innovative, untested, potentially groundbreaking concepts in prostate cancer. **LOI Due:** June 22, 2023
- **Idea Development Award (IDA)** - supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research and have the potential to make an important contribution to one or more of the FY23 PCRP Overarching Challenges. **LOI Due:** June 29, 2023
- **Physician Research Award (PRA)** - supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research. **LOI Due:** August 3, 2023

[Read More](#)

Center for GI Cancers Seminar Series 2022-2023

April 20, 4:15 PM

[Learn More](#)

Yale CCEH Rising Stars in Hematology Series

April 21, 12:00 PM

Next generation expansion microscopy with universal anchoring strategy and its application in hematology

Yongxin (Leon) Zhao, Ph.D.

[Learn More](#)

Yale Center for Immuno-Oncology Seminar

April 21, 2:00 PM

BML 131

A vascular-restricted, tumor-induced neutrophil population drives vascular occlusion, pleomorphic necrosis, and metastasis

Jose Adrover Montemayor, PhD

[Learn More](#)

Yale Cancer Answers

April 23, 7:30 PM

Sickle Cell Disease and the Care of Bleeding and Clotting Disorders

Layla Van Doren, MD, MBA

[Learn More](#)

MB&B Seminar

April 24, 4:00 PM

Bass Center

Structure and Function of the HIV-1 Capsid

Wes Sundquist, Professor of Biochemistry

[Learn More](#)

Yale Cancer Center Grand Rounds

April 25, 12:00 PM

Auditorium, 55 Park Street

The Second Century in the Land of Small Tumors

James Yao, Professor and Chair,

Department of Gastrointestinal Medical Oncology

[Learn More](#)

Schwartz Center Rounds

April 26, 12:00 PM

Physical Safety In The Workplace - Providers Perspective

Moderated by: Krista Bello, RN, OCN

[Learn More](#)

Neuroendocrine Series

April 26, 4:00 PM

Radiation Therapy for Pituitary Tumors

James E. Hansen, MD, MS

Learn More

YCC/Smilow Cancer Hospital Town Hall

April 26, 5:00 PM

Eric Winer, MD | Kevin Billingsley, MD, MBA,

FACS | Lori Pickens, MHA | Jeremy

Kortmansky, MD | Sarah Elizabeth

Schellhorn, MD | Elizabeth Herbert | Lisa

Shomsky, MBA, BSN, CNML

Learn More

**Protein Profiling by Mass Spectrometry:
From Biological Concept to Functional
Output, and the Nook and Cranny in
Between**

April 27, 10:00 AM

Sterling Hall of Medicine, C-Wing

TuKiet Lam, PhD, BA

Learn More

Immunobiology Seminar Series

April 27, 10:30 AM

*Exploring the tumor-immune ecosystem
using computational modeling*

Stacey Finley, PhD

Learn More



Share your news!

Please submit your recent publications, awards,
and grant announcements to:

[Renee Gaudette](#)

Director, Public Affairs and Communications

Yale Cancer Center | 333 Cedar Street, New Haven, CT 06520

[Unsubscribe renee.gaudette@yale.edu](#)

[Update Profile](#) | [Constant Contact Data
Notice](#)

Sent by renee.gaudette@yale.edu powered by



Try email marketing for free today!